Page last updated: 2024-12-06

ranitidine hydrochloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ranitidine hydrochloride is a histamine H2 receptor antagonist used to treat ulcers, gastroesophageal reflux disease (GERD), and Zollinger-Ellison syndrome. It was synthesized in the 1970s by researchers at GlaxoSmithKline. Ranitidine works by blocking the action of histamine on the stomach, reducing the production of stomach acid. It was one of the first drugs in its class and was widely used for many years. However, it has since been withdrawn from the market due to concerns about the presence of the probable carcinogen N-Nitrosodimethylamine (NDMA) in the drug. Ranitidine was important as it provided an effective treatment for acid-related disorders and was widely studied to understand its mechanism of action and potential side effects. Its importance in the pharmaceutical market led to its eventual replacement by safer alternatives.'

label : A role played by a part of a molecular entity distinguishable by the observer but not by the system and used to identify a tracer. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID47909
CHEMBL ID2110372
SCHEMBL ID33299
MeSH IDM0353202
PubMed CID3033332
CHEMBL ID1092473
CHEBI ID8777
MeSH IDM0353202

Synonyms (213)

Synonym
ranitidin duncan
ran
ranitidin atid
esofex
ranitidin awd
normon
ranitidina predilu grif
ranitidin-cophar
ranitidin basics
digestosan
ranicux
noktome
ranitidin dyna
rubiulcer
serviradine
ranidin
ranilonga
ranic
ranitidin-isis
ranitidin nm
n-(2-((5-((dimethylamino)methyl)furfuryl)thio)ethyl)-n'-methyl-2-nitrovinylidenediamine hydrochloride
ulcecur
neugal
artomil
rani-sanorania
ranigasan
ranitidin-ratiopharm
regalil
viserul
alter-h2
rozon
ranitine
ranigen
ranitidin stada
einecs 266-333-0
ranitidin normon
ccris 5268
1,1-ethenediamine, n-(2-(((5-((dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-n'-methyl-2-nitro-, monohydrochloride
ranisan
ranitidin von ct
ergan
novo-radinine
coralen [inj.]
ranimerck
ran lich
quadrin
rani abz
lake
ah 19065
renatac
ranitidine hydrochloride [usp:jan]
ranitidin al
ranuber
ranitidin hexal
ranidura
ranigast
n-(2-(((5-((dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-n'-methyl-2-nitro-1,1-ethenediamine, hydrochloride
ulcolind rani
ranitidin pb
ranitidin
ranidil
ulsaven
ranitab
ranobel
ranitidin merck
rani 2
zandid
zantarac
alvidina
ulcirex
ranitidina tamarang
ran h2
raniberta
label
ranitidin 1a pharma
rani-basf
mideran
ranifur [inj.]
rani-puren
ranitic
ranitidin heumann
ranitidin arcana
ulcodin
pep-rani
logat
ranitidin millet
quantor [inj.]
apo-ranitidin
azuranit
ranitidin helvepharm
taladine
CHEMBL2110372
trigger [drug]
ranifur
bk76465ihm ,
unii-bk76465ihm
zantac efferdose
AB02807
ranitidine hydrochloride [usp-rs]
ranitidine hydrochloride [ep monograph]
ranitidine hydrochloride [who-dd]
ranitidine hydrochloride [jan]
ranitidine hydrochloride [mart.]
ranitidine hydrochloride [usp monograph]
ranitidine hydrochloride [orange book]
ranitidine hydrochloride [ep impurity]
ranitidine hydrochloride [mi]
ranitidine hydrochloride [vandf]
GGWBHVILAJZWKJ-UHFFFAOYSA-N
n-[2-[[[5-(dimethylamino)methyl-2-furanyl]methyl]thio]ethyl]-n'-methyl-2-nitro-1,1-ethenediamine hydrochloride
SCHEMBL33299
AKOS030228564
ranitidine hydrochloride 1.0 mg/ml in methanol (as free base)
ranitidine hydrochloride,(s)
Q27108147
ranitidine hydrochloride (1:1)
DTXSID201015892
n-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-n'-methyl-2-nitro-1,1-ethenediamine hydrochloride
71130-06-8
AC-12743
smr000653467
MLS001146938
tanidina
azantac
toriol
zantic
ah-19065
EU-0101073
zantac 300
zantac 150
zantac in plastic container
ranitidine hcl
radin
santanol
zantac 75
c13h22n4o3s.hcl
PRESTWICK_635
raniben
CHEBI:8777 ,
ranibeta
BIM-0051043.0001
66357-59-3
ranitidine hydrochloride (jp17/usp)
D00673
NCGC00094351-01
ah19065
hydrochloride, ranitidine
R-101
R0073
n-[2-[5-[(dimethylamino)methyl]furfurylthio]ethyl]-n'-methyl-2-nitro-1,1-ethenediamine hydrochloride
HMS1568J03
CHEMBL1092473
A835435
(e)-n1'-[2-[[5-[(dimethylamino)methyl]-2-furanyl]methylthio]ethyl]-n1-methyl-2-nitroethene-1,1-diamine hydrochloride
(e)-n1'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-n1-methyl-2-nitro-ethene-1,1-diamine hydrochloride
MLS002548856
einecs 275-207-4
n-(2-((5-((dimethylamino)methyl)furfuryl)thio)ethyl)-n'-methyl-2-nitrovinylidenediamine monohydrochloride
1,1-ethenediamine, n-(2-(((5-((dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-n'-methyl-2-nitro-, hydrochloride
ranitidine.hcl
zantac 25
LP01073
EPITOPE ID:127516
S1801
AKOS015895250
CCG-212946
HY-B0281A
ranitidine (hydrochloride)
NC00479
HS-1000 ,
NCGC00261758-01
tox21_501073
W-104534
HB2630
n-[2-[[[5-[(dimethylamino)methyl]-2 -furanyl]methyl]thio]ethyl]-n'-methyl-2-nitro-1,1-e thanediamine hydrochloride
(e)-n-(2-(((5-((dimethylamino)methyl)furan-2-yl)methyl)thio)ethyl)-n'-methyl-2-nitroethene-1,1-diamine hydrochloride
SR-01000075288-2
ranitidine (zantac)
{2-[({5-[(dimethylamino)methyl]furan-2-yl}methyl)sulfanyl]ethyl}[(z)-1-(methylamino)-2-nitroethenyl]amine hydrochloride
SW196800-3
n-(2-(((5-((dimethylamino)methyl)furan-2-yl)methyl)thio)ethyl)-n'-methyl-2-nitroethene-1,1-diamine hydrochloride
GGWBHVILAJZWKJ-KJEVSKRMSA-N
n-[2-[[5-(dimethylaminomethyl)furan-2-yl]methylsulfanyl]ethyl]-n'-methyl-2-nitroethene-1,1-diamine hydrochloride
n-(2-((5-(dimethylaminomethyl)furan-2-yl)methylsulfanyl)ethyl)-n'-methyl-2-nitroethene-1,1-diamine hcl
BCP28420
zantac;noctone
AMY24712
(e)-1-n'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-n-methyl-2-nitroethene-1,1-diamine;hydrochloride
ranitidine hydrochloride 100 microg/ml in acetonitrile
n-(2-(((5-((dimethylamino)methyl)furan-2-yl)methyl)thio)ethyl)-n-methyl-2-nitroethene-1,1-diaminehydrochloride
ranitidine for impurity a identification
Z3247239485
(1ez)-n-(2-(((5-((dimethylamino)methyl)furan-2-yl)methyl)sulfanyl)ethyl)-n'-methyl-2-nitroethene-1,1-diamine monohydrochloride
ranitidineimmediate release
ranitidine hydrochloride (ep impurity)
ranitidine hydrochloride tablets 150mg
ranitidine hydrochloride (mart.)
ranitidine tablet usp, 75mg
ranitidine-acid reducer
ranitidinecool mint
ranitidine hydrochloride (ep monograph)
regular strength acid reducer
wal-zan
ranitidine 75
ranitidine tablets usp, 75mg
acid reducer 150
ranitidine hydrochloride (usp-rs)
heratburn relief
ranitidine 150
aptidine75
wal-zan 75
ranitidine hydrochloride (usp monograph)
ranitidine hydrochloride oral suspension kit

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Testing of biological activity revealed limited potential for resistance to these agents, low toxicity, and highly effective in vivo activity, even with low dosing regimens."( Antibacterial activity of a series of N2,N4-disubstituted quinazoline-2,4-diamines.
Burda, WN; Fleeman, R; Manetsch, R; Shaw, LN; Van Horn, KS, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
drug allergenAny drug which causes the onset of an allergic reaction.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
hydrochlorideA salt formally resulting from the reaction of hydrochloric acid with an organic base.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thioredoxin reductaseRattus norvegicus (Norway rat)Potency47.28640.100020.879379.4328AID588453
ATAD5 protein, partialHomo sapiens (human)Potency23.09990.004110.890331.5287AID504467
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency70.79460.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency2.51190.540617.639296.1227AID2364; AID2528
M-phase phosphoprotein 8Homo sapiens (human)Potency89.12510.177824.735279.4328AID488949
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA repair protein RAD52 homolog isoform aHomo sapiens (human)AC5011.76000.150012.066235.2100AID652116
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID1160939Effective permeability of the compound at pH 4 by PAMPA2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium.
AID576507Antiplasmodial activity against Plasmodium falciparum 3D7 infected in RBCs by firefly luciferase reporter gene assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay.
AID1160934Effective permeability of the compound at pH 7.4 by PAMPA2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium.
AID1138688Permeability of the compound at pH 4 by PAMPA2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Antibacterial activity of a series of N2,N4-disubstituted quinazoline-2,4-diamines.
AID1138687Permeability of the compound at pH 7.4 by PAMPA2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Antibacterial activity of a series of N2,N4-disubstituted quinazoline-2,4-diamines.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1154496Passive transcellular permeability of the compound at pH 4 by PAMPA2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Antileishmanial activity of a series of N²,N⁴-disubstituted quinazoline-2,4-diamines.
AID474786Membrane permeability at 10 uM at pH 7.4 by PAMPA method2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Synthesis and structure-activity relationships of antimalarial 4-oxo-3-carboxyl quinolones.
AID1154495Passive transcellular permeability of the compound at pH 7.4 by PAMPA2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Antileishmanial activity of a series of N²,N⁴-disubstituted quinazoline-2,4-diamines.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (13.33)29.6817
2010's11 (73.33)24.3611
2020's2 (13.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 92.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index92.40 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index158.08 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (92.40)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]